Article Text

PDF
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice
  1. Bert Vander Cruyssen1,
  2. Clio Ribbens2,
  3. Annelies Boonen3,
  4. Herman Mielants1,
  5. Kurt de Vlam4,
  6. Jan Lenaerts5,
  7. Serge Steinfeld6,
  8. Filip Van den Bosch1,
  9. Lode Dewulf7,
  10. Nathan Vastesaeger7
  1. 1Ghent University, Ghent, Belgium
  2. 2University Hospital Sart Tilman, Liege, Belgium
  3. 3University Hospital, Maastricht, Netherlands
  4. 4University Hospital, Leuven, Belgium
  5. 5Virga Jesse hospital, Hasselt, Belgium
  6. 6Erasme University Hospital, Brussels, Belgium
  7. 7Schering Plough, Brussels, Belgium
  1. Correspondence to:
    Bert Vander Cruyssen
    Rheumatology Department, Ghent University Hospital, De Pintelaan 185, 90000 Ghent, Belgium; Bert.VanderCruyssen{at}Ugent.be

Abstract

Objectives: This study aimed to describe the epidemiology of ankylosing spondylitis (AS) in rheumatology practice at the beginning of the anti-TNF (tumour necrosis factor) era, and to evaluate the initiation of anti-TNF therapy in a clinical setting where prescription is regulated by the authority’s imposed reimbursement criteria.

Methods: Between February 2004 and February 2005, all Belgian rheumatologists in academic and non-academic outpatient settings were invited to register all AS patients who visited their practice. A random sample of these patients was further examined by an in-depth clinical profile. In a follow-up investigation, we recorded whether patients initiated anti-TNF therapy and compared this to their eligibility at baseline evaluation.

Results: 89 rheumatologists participated and registered 2141 patients; 1023 patients were clinically evaluated. These 847 fulfilled the New York modified criteria for definite AS and 176 for probable AS. The profile of AS in rheumatology practice is characterised by longstanding and active disease with a high frequency of extra-articular manifestations and metrological and functional impairment. At a median of 2 months after the clinical evaluation, anti-TNF therapy was initiated in 263 of 603 (44%) evaluable patients with definite AS and in 22 of 138 (16%) evaluable patients with probable AS (total 38%). More than 85% of the patients who started anti-TNF therapy had an increased Bath Ankylosing Spondylitis Disease Activity Index despite previous NSAID (non-steroidal anti-inflammatory drug) use.

Conclusions: Of a representative cohort of 1023 Belgian AS patients seen in daily rheumatology practice, about 40% commenced anti-TNF therapy. Decision factors to start anti-TNF therapy may include disease activity and severity.

  • AS, ankylosing spondylitis
  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index
  • BASFI, Bath Ankylosing Spondylitis Functionality Index
  • BASMI, Bath Ankylosing Spondylitis Metrology Index
  • CRP, C reactive protein
  • DMARDs, disease modifying antirheumatic drugs
  • IBD, inflammatory bowel disease
  • MTX, methotrexate
  • NSAID, non-steroidal anti-inflammatory drug
  • SpA, spondyloarthropathy
  • TNF, tumour necrosis factor
  • ankylosing spondylitis
  • epidemiology
  • anti-TNF therapy
  • daily clinical practice

Statistics from Altmetric.com

Footnotes

  • Published Online First 29 January 2007

  • Bert Vander Cruyssen was supported by a concerted action grant GOA 2001/12051501 from Ghent University, Belgium.

  • Competing interests: LD and NV were employees of Schering-Plough during the study. KDV received consulting fees from Shering-Plough, Centocor, and Wyeth. BVC, CR, HM, AB, JL, and SS received speaker fees from Shering-Plough.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.